TANDEM DIABETES CARE INC shareholders approved To ratify the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026. at the 2026-05-20 meeting.
“Proposal 6 : To ratify the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. This proposal was approved and the voting results were as follows: For Against Abstain Broker Non-Votes 57,493,084 454,735 16,556 0”
Shareholder Votes
TANDEM DIABETES CARE INC shareholders approved To approve an amendment to the Company's Amended and Restated Certificate of Incorporation to, among other things, (i) limit the liability of officers of the Company to the maximum extent permitted by law as permitted pursuant to Section 102(b)(7) of the DGCL, and (ii) implement certain other change at the 2026-05-20 meeting.
“Proposal 5 : To approve an amendment to the Company’s Amended and Restated Certificate of Incorporation to, among other things, (i) limit the liability of officers of the Company to the maximum extent permitted by law as permitted pursuant to Section 102(b)(7) of the DGCL, and (ii) implement certain other changes based on updates to the DGCL. This proposal was approved and the voting results were as follows: For Against Abstain Broker Non-Votes 45,926,405 9,043,831 15,058 2,979,081”
Shareholder Votes
TANDEM DIABETES CARE INC shareholders approved To approve an amendment to the Company's Amended and Restated Certificate of Incorporation to provide for removal of directors with or without cause, as required by Section 141(k) of the DGCL. at the 2026-05-20 meeting.
“Proposal 4 : To approve an amendment to the Company’s Amended and Restated Certificate of Incorporation to provide for removal of directors with or without cause, as required by Section 141(k) of the DGCL. This proposal was approved and the voting results were as follows: For Against Abstain Broker Non-Votes 57,818,029 126,025 20,321 0”
Shareholder Votes
TANDEM DIABETES CARE INC shareholders approved To approve the Amended Plan to, among other things, increase the number of shares authorized for issuance under the plan. at the 2026-05-20 meeting.
“Proposal 3 : To approve the Amended Plan to, among other things, increase the number of shares authorized for issuance under the plan. This proposal was approved and the voting results were as follows: For Against Abstain Broker Non-Votes 53,846,696 1,108,529 30,069 2,979,081”
Shareholder Votes
TANDEM DIABETES CARE INC shareholders approved To approve, on a non-binding, advisory basis, the compensation of the Company's named executive officers as described in the Proxy Statement. at the 2026-05-20 meeting.
“Proposal 2 : To approve, on a non-binding, advisory basis, the compensation of the Company’s named executive officers as described in the Proxy Statement. This proposal was approved and the voting results were as follows: For Against Abstain Broker Non-Votes 53,460,747 1,481,027 43,520 2,979,081”
Shareholder Votes
TANDEM DIABETES CARE INC shareholders approved To elect nine directors for a one-year term expiring at the 2027 annual meeting of stockholders. at the 2026-05-20 meeting.
“Proposal 1 : To elect nine directors for a one-year term expiring at the 2027 annual meeting of stockholders. The stockholders elected nine directors by the following votes: Name of Director For Against Abstain Broker Non-Votes Rebecca Robertson 54,160,282 799,310 25,702 2,979,081 Sandra Beaver 54,607,191 348,050 30,053 2,979,081 Myoungil Cha 54,456,358 502,290 26,646 2,979,081 Peyton Howell 54,179,597 773,220 32,477 2,979,081 Joao Malagueira 54,454,159 499,747 31,388 2,979,081 Kathleen McGroddy-Goetz 54,312,399 641,726 31,169 2,979,081 John Sheridan 54,432,569 536,164 16,561 2,979,081 2 Rajwant Sodhi 54,328,131 621,295 35,868 2,979,081 Christopher Twomey 47,921,655 7,034,208 29,431 2,979,081”
Mark Novara was terminated as Executive Vice President and Chief Commercial Officer at TANDEM DIABETES CARE INC.
“On May 11, 2026, Mark Novara, the Executive Vice President and Chief Commercial Officer of Tandem Diabetes Care, Inc. (the “Company”), was notified that his employment with the Company is being terminated without cause.”
Equity Issuances
TANDEM DIABETES CARE INC issued convertible note to initial purchasers for $300.0 million aggregate principal amount.
“Material Agreement. Indenture and Notes On February 27, 2026, Tandem Diabetes Care, Inc. (the “Company”) completed its previously announced private offering (the “Offering”) of $300.0 million aggregate principal amount of 0.00% Convertible Senior Notes due 2032 (the “Notes”), including the exercise in full of the initial purchasers’ option to purchase up to an”
Debt Financings
TANDEM DIABETES CARE INC incurred convertible notes of $300.0 million aggregate principal amount with U.S. Bank Trust Company, National Association at 0.00% maturing March 15, 2032.
“On February 27, 2026, Tandem Diabetes Care, Inc. (the “Company”) completed its previously announced private offering (the “Offering”) of $300.0 million aggregate principal amount of 0.00% Convertible Senior Notes due 2032 (the “Notes”), including the exercise in full of the initial purchasers’ option to purchase up to an additional $35.0 million principal amount of Notes.”
Material Agreements
TANDEM DIABETES CARE INC entered into Indenture with U.S. Bank Trust Company, National Association valued at $300.0 million aggregate principal amount (effective 2026-02-27).
“On February 27, 2026, Tandem Diabetes Care, Inc. (the “Company”) completed its previously announced private offering (the “Offering”) of $300.0 million aggregate principal amount of 0.00% Convertible Senior Notes due 2032 (the “Notes”), including the exercise in full of the initial purchasers’ option to purchase up to an additional $35.0 million principal amount of Notes. The Notes were issued in accordance with an indenture, dated February 27, 2026 (the “Indenture”), between the Company and U.S. Bank Trust Company, National Association, as trustee.”
Governance Changes
TANDEM DIABETES CARE INC: Amended and Restated Bylaws effective December 26, 2025, updating advance notice provisions, meeting cancellation authority, proxy card color rule, indemnification, notice provisions, voting standards, stockholder list requirement, and certain technical changes (effective 2025-12-26).
“On December 26, 2025, in connection with a standard periodic review of the governance documents of Tandem Diabetes Care, Inc. (the “Company”), the Company’s board of directors (the “Board”) adopted Amended and Restated Bylaws of the Company (the “Amended and Restated Bylaws”), which became effective immediately and amended and restated the Company’s prior bylaws (the “Prior Bylaws”).”
Jean-Claude Kyrillos was appointed as Chief Operating Officer at TANDEM DIABETES CARE INC.
“On June 19, 2024, the Board of Directors of Tandem Diabetes Care, Inc. (the “Company”) approved the appointment of Jean-Claude Kyrillos as Executive Vice President, Chief Operating Officer effective June 21, 2024.”
Material Agreements
TANDEM DIABETES CARE INC amended Amendment Number 1 with Unomedical a/s (effective 2024-05-10).
“On May 10, 2024, Tandem Diabetes Care, Inc., a Delaware corporation (the “Company”) and Unomedical a/s, a Danish corporation and a subsidiary of the ConvaTec Group (“Unomedical”), entered into Amendment Number 1 (“Amendment 1”) to the Distributor Agreement, dated as of January 14, 2022, between the Company and Unomedical, under which Unomedical manufactures, tests, sterilizes and packs all of the infusion sets under the Company’s brands (the “Original Agreement”).”
Debt Financings
TANDEM DIABETES CARE INC incurred convertible notes of $316.25 million aggregate principal amount with U.S. Bank Trust Company, National Association at 1.50% per year maturing March 15, 2029.
“On March 8, 2024, Tandem Diabetes Care, Inc. (the “Company”) completed its previously announced private offering (the “Offering”) of $316.25 million aggregate principal amount of 1.50% Convertible Senior Notes due 2029 (the “Notes”), including the exercise in full of the initial purchasers’ option to purchase up to an additional $41.25 million principal amount of Notes.”
Material Agreements
TANDEM DIABETES CARE INC entered into Indenture with U.S. Bank Trust Company, National Association valued at $316.25 million aggregate principal amount (effective 2024-03-08).
“Indenture and Notes On March 8, 2024, Tandem Diabetes Care, Inc. (the “Company”) completed its previously announced private offering (the “Offering”) of $316.25 million aggregate principal amount of 1.50% Convertible Senior Notes due 2029”
David B. Berger departed as Executive Vice President and Chief Operating Officer at TANDEM DIABETES CARE INC.
“on November 7, 2023, the Company and David B. Berger, the Company’s Executive Vice President and Chief Operating Officer, determined that Mr. Berger will be stepping down from his current position effective December 31, 2023.”
David B. Berger departed as Executive Vice President and Chief Operating Officer at TANDEM DIABETES CARE INC.
“On November 7, 2023, Tandem Diabetes Care, Inc. (“Tandem” or the “Company”) and David B. Berger, the Company’s Executive Vice President and Chief Operating Officer, determined that he will be stepping down from his current position effective December 31, 2023.”
Brian B. Hansen resigned as Executive Vice President and Chief Commercial Officer at TANDEM DIABETES CARE INC.
“On August 17, 2023, Brian B. Hansen, Executive Vice President and Chief Commercial Officer of Tandem Diabetes Care, Inc. (the Company), notified the Company of his decision to resign from his role as Executive Vice President and Chief Commercial Officer, effective December 31, 2023.”
Shareholder Votes
TANDEM DIABETES CARE INC shareholders approved To ratify of the appointment of Ernst & Young LLP to serve as the Company's independent registered public accountant for the year ending December 31, 2023. at the 2023-05-24 meeting.
“Proposal 4 : To ratify of the appointment of Ernst & Young LLP to serve as the Company's independent registered public accountant for the year ending December 31, 2023. The proposal received the following votes: For Against Abstain Broker Non-Votes 58,058,014 790,996 65,483”
Shareholder Votes
TANDEM DIABETES CARE INC shareholders approved To approve, on a non-binding, advisory basis, the compensation of the Company's named executive officers. at the 2023-05-24 meeting.
“Proposal 3 : To approve, on a non-binding, advisory basis, the compensation of the Company's named executive officers. The proposal received the following votes: For Against Abstain Broker Non-Votes 45,684,932 10,258,454 50,633 2,920,474”
Shareholder Votes
TANDEM DIABETES CARE INC shareholders approved To approve the Company's 2023 Long-Term Incentive Plan, which will replace the 2013 Stock Incentive Plan expiring on November 15, 2023. at the 2023-05-24 meeting.
“Proposal 2 : To approve the Company's 2023 Long-Term Incentive Plan, which will replace the 2013 Stock Incentive Plan expiring on November 15, 2023. The proposal received the following votes: For Against Abstain Broker Non-Votes 51,791,463 4,104,680 97,876 2,920,474”
Earnings Releases
TANDEM DIABETES CARE INC reported financial results for quarter and year ended December 31, 2022.
“On February 22, 2023, we issued a press release reporting our f inancial results for the quarter and year ended December 31, 2022.”
John Allen changed role as Lead Independent Director at TANDEM DIABETES CARE INC.
“Mr. Allen will transition from the role of Lead Independent Director to a member of the Board.”
Rebecca Robertson was appointed as Chair of the Board at TANDEM DIABETES CARE INC.
“Rebecca Robertson will succeed Kim D. Blickenstaff as Chair of the Board of Directors (the “Board”), effective March 1, 2023.”
Kim D. Blickenstaff changed role as Chair of the Board at TANDEM DIABETES CARE INC.
“Mr. Blickenstaff will transition from the role of Chair of the Board to a member of the Board”
M&A Transactions
TANDEM DIABETES CARE INC completed an acquisition involving AMF Medical SA for a previous strategic investment of Swiss Francs ("CHF") 8.0 million paid in the third quarter of 2022, a cash payment of CHF 62.4 million paid at the closing of (closed 2023-01-19).
“e Company entered into a Share Purchase Agreement, dated as of December 10, 2022 (the “Purchase Agreement”), by and among the Company, the Sellers listed on Annex B of the Purchase Agreement (collectively, the “Sellers” and each, individually, a “Seller”) and AMF Medical SA, a corporation organized and existing under the laws of Switzerland (“AMF Medical”).”
Earnings Releases
TANDEM DIABETES CARE INC updated its the quarter and full year ended December 31, 2022 guidance (initiated).
“On January 10, 2023 , the Company issued a press release announcing its unaudited, preliminary financial results for the quarter and full year ended December 31, 2022, as well as its preliminary financial guidance for the full year ending December 31, 2023.”
Material Agreements
TANDEM DIABETES CARE INC entered into Share Purchase Agreement with the Sellers listed on Annex B attached thereto and AMF Medical SA valued at CHF 62.4 million (effective 2022-12-10).
“On December 10, 2022 , Tandem Diabetes Care, Inc., a Delaware corporation (the “Company”), entered into a Share Purchase Agreement (the “Purchase Agreement”) with the Sellers listed on Annex B attached thereto (collectively, the “Sellers” and each, individually, a “Seller”) and AMF Medical SA, a corporation organized and existing under the laws of Switzerland (“AMF Medical”).”
Joao Malagueira was elected as Director at TANDEM DIABETES CARE INC.
“elected Joao Malagueira, age 56, to serve as a Class I director on the Board”
Myoung Cha was elected as Director at TANDEM DIABETES CARE INC.
“elected Myoung Cha, age 45, to serve as a Class III director on the Board”
Douglas A. Roeder departed as Director at TANDEM DIABETES CARE INC.
“On March 11, 2022, Douglas A. Roeder, notified the Company of his decision not to stand for re-election at the Company’s 2022 Annual Meeting of Stockholders”
David B. Berger was appointed as Executive Vice President, Chief Operating Officer and Assistant Secretary at TANDEM DIABETES CARE INC.
“On February 3, 2022, the Board of Directors appointed David B. Berger, age 52, to serve as the Company’s Executive Vice President, Chief Operating Officer and Assistant Secretary.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.